# Thymosin Alpha-1 vs Thymosin Beta-4: How They Differ

> Thymosin Alpha-1 vs Thymosin Beta-4 (TB-500): different sequence, size, mechanism, and use. One is an immune peptide; the other is an actin-binding repair peptide.

Same first name, two unrelated molecules. Here is the distinction the internet keeps blurring.

## The short version

People constantly mix these up because they share a name, but Thymosin Alpha-1 vs Thymosin Beta-4 is a comparison of two genuinely different molecules. Thymosin Alpha-1 is a 28-amino-acid *immune* peptide — it helps immune cells mature and coordinate, and its drug form is thymalfasin [1]. Thymosin Beta-4 (sold in research circles as TB-500) is a larger 43-amino-acid peptide that binds a structural protein called actin and is studied for *tissue repair*, not immunity. They differ in sequence, size, the receptors and proteins they act on, and what researchers use them for. They are not interchangeable, and one is not a "version" of the other. If you came looking for a muscle or recovery peptide, Thymosin Alpha-1 is not it.

## Different molecules, not variants

The shared word "thymosin" is historical: both were first found in thymic extracts, but they belong to separate peptide families. **Thymosin Alpha-1** is a 28-amino-acid, N-terminally acetylated peptide cleaved from the precursor prothymosin alpha; it has no disulfide bonds and no aromatic residues, and the synthetic drug thymalfasin is sequence-identical [1]. **Thymosin Beta-4** is a 43-amino-acid peptide from the beta-thymosin family whose defining job is sequestering monomeric actin inside cells. Their amino-acid sequences are unrelated; knowing one tells you nothing about the other's structure.

## Different mechanisms, different uses

Mechanistically they barely overlap. Thymosin Alpha-1 signals through Toll-like receptors on dendritic cells, matures T-cells toward a Th1 program, and engages an IDO-driven regulatory arm — an immunomodulator end to end [5]. Its clinical record is in chronic viral hepatitis, immune restoration, and adjuvant cancer settings [9][7]. Thymosin Beta-4, by contrast, is studied for its roles in cell migration, angiogenesis, and wound healing through actin dynamics — a tissue-repair story, not an immune one. Using one where the other is indicated would be using the wrong tool entirely.

## The doping-status difference matters

There is a practical regulatory gap, too. Thymosin Beta-4 (TB-500) is the one explicitly named on the WADA Prohibited List and is the peptide athletes are warned about. Thymosin Alpha-1 is not specifically listed as a named prohibited substance — though immunomodulatory peptides occupy a grey area and the current WADA List should always be the reference. The point for this comparison: the two molecules sit in different places regulatorily as well as biologically. Confusing them is not a harmless naming slip.

## Bottom line

Thymosin Alpha-1 vs Thymosin Beta-4 comes down to four clean differences: sequence (unrelated 28-mer vs 43-mer), size, mechanism (immune signalling vs actin binding), and use (viral/immune/cancer adjuvant vs tissue repair). They are not the same compound, not two grades of one product, and not substitutes. This site is about the immune peptide — Thymosin Alpha-1 — and its forward-read but honestly-graded evidence base [3].

---

A forward but evidence-graded reading of the Thymosin Alpha-1 record — the four-decade hepatitis and immune-restoration signal read first, the null phase-3 sepsis trial held in plain view, the molecule kept distinct from thymosin beta-4, and the community reports fenced off as unverified; an open reading desk, not a clinic, and nothing here dosed, sourced, prescribed, or sold.